Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human type I collagen lyophilized fibers
- Development stage
- Unknown
- Lead developer
- Shanxi Jinbo Bio-Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intradermal
01
Overview
Human type I collagen lyophilized fibers is a recombinant humanized collagen product developed for aesthetic dermatology, specifically for the correction of dynamic facial wrinkles such as crow's feet. The product consists of highly purified type I collagen fibers, the primary structural protein of the human dermis, produced via recombinant DNA technology to ensure high biocompatibility and low immunogenicity compared to animal-derived collagen. Upon intradermal injection, the fibers provide immediate mechanical volume to smooth wrinkles and act as a bioactive scaffold that supports fibroblast adhesion and the synthesis of endogenous collagen. This dual action helps restore the structural integrity of the extracellular matrix and provides long-lasting aesthetic improvement. It is being evaluated in clinical trials, including long-term follow-up studies, to assess its safety and durability of effect.
- Other names
- recombinant humanized type I collagen lyophilized fibersrecombinant human type I collagenhuman type I collagen lyophilized fibers
02
Targets
Neuraminidase
Beyond the preview
Go deeper on human type I collagen lyophilized fibers.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human type I collagen lyophilized fibers.